Weifang Ruze New Material Co., Ltd.

 

Your Aspiration is Our Commitment

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home ProductsNon Small Cell Lung Cancer Medications

Non Small Cell Lung Cancer Medications Crizotinib CAS New Medication For Lung Cancer

Ruze supply good service, thanks.

—— Gaurav

I'm Online Chat Now

Non Small Cell Lung Cancer Medications Crizotinib CAS New Medication For Lung Cancer

China Non Small Cell Lung Cancer Medications Crizotinib CAS New Medication For Lung Cancer supplier
Non Small Cell Lung Cancer Medications Crizotinib CAS New Medication For Lung Cancer supplier Non Small Cell Lung Cancer Medications Crizotinib CAS New Medication For Lung Cancer supplier

Large Image :  Non Small Cell Lung Cancer Medications Crizotinib CAS New Medication For Lung Cancer

Product Details:

Place of Origin: Weifang,China
Brand Name: RuzE
Model Number: TC-9032

Payment & Shipping Terms:

Minimum Order Quantity: Negotiable
Price: Negotiable
Packaging Details: 25g
Delivery Time: 5-10workdays
Payment Terms: L/C, T/T, Western Union, MoneyGram
Supply Ability: 25kg/Month
Contact Now
Detailed Product Description
Product Name: Crizotinib CAS: 877399-52-5
MF: C21H22Cl2FN5O MW: 450.343
EINECS: 638-814-9 Mol File: 877399-52-5.mol

Weifang Ruze New Material Co.,LTD a China supplier of Crizotinib (CAS No.: 877399-52-5),CAS 877399-52-5offers for your requirements of RND, evaluation, pilots and commercial along with supportive technical package required for evaluation.

Non Small Cell Lung Cancer Medications Crizotinib CAS New Medication For Lung Cancer

 

Crizotinib

 

[Product Name]: Crizotinib
[Synonyms]:PF-2341066; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-Pyridinamine;(R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine;3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]pyridin-2-amine;Crizotinib;PF 2341066;PF-02341066;PF-2341066/Crizotinib;3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine
[CAS]: 877399-52-5
[MF]: C21H22Cl2FN5O
[MW]: 450.343
[Purity]: 99%
[Appearance]: White Crystalline Powder
 

[Crizotinib COA]:


Test Items

Specification

Results

Description

White to off white crystalline powder

Comply

Melting point

166-170°C

167.3-168.1°C

Identification

Positive reaction

Positive reaction

Related substances

≤1.0%

0.16%

Loss on drying

≤0.5%

0.06%

Residue on ignition

≤0.1%

0.02%

Chloride

≤0.014%

<0.014

Heavy Metals

≤20ppm

<20ppm

Clarity of solution

Conform to standard

Complies

Microbial Limit

≤20ppm

<20ppm

Assay

≥99.0%

99.12%


Crizotinib is an anti-cancer drug.Crizotinib has an aminopyridine structure, and functions as a protein kinase inhibitor by competitive binding within the ATP-binding pocket of target kinases.Crizotinib is currently thought to exert its effects through modulation of the growth, migration, and invasion of malignant cells.Other studies suggest that crizotinib might also act via inhibition of angiogenesis in malignant tumors.

 

[Packing]:
1. Food bag packing( Disguised package)
Usually products are send in discreet way,based on our rich in shipping products to every countries,we usually use disguised way.
The photo of food disguised package for your reference,which has passed through every countries smoothly,products are packed well in food box,which mixed with real visible chinese food,and in the express bill we will declare food and sample,customs just think it chinese food and release it.


Crizotinib Chemical Properties


storage temp. room temp
form powder
color white to tan
CAS DataBase Reference 877399-52-5
 

Safety Information


 

Safety Statements 24/25
RIDADR UN 3077 9 / PGIII
WGK Germany 3
HazardClass IRRITANT
HS Code 29333990

 


Crizotinib Usage And Synthesis


Biological Activity Potent inhibitor of c-MET and anaplastic lymphoma kinase (ALK) (cell IC50 values are 8.0 and 20 nM respectively). Selective for c-MET and ALK against >120 different kinases. Displays antitumor efficacy in multiple tumor models; inhibits c-MET-dependent proliferation, migration and invasion of human tumor cells in vitro. Orally bioavailable.
Mechanism of action Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), and Recepteur d’Origine Nantais (RON). Translocations can affect the ALK gene resulting in the expression of oncogenic fusion proteins. The formation of ALK fusion proteins results in the activation and dysregulation of the gene's expression and signaling, which can contribute to increased cell proliferation and survival in tumors expressing these proteins. Crizotinib demonstrates concentration-dependent inhibition of ALK and c-Met phosphorylation in cell-based assays using tumor cell lines, and also demonstrates antitumor activity in mice bearing tumor xenografts that express EML4-or NPM-ALK fusion proteins or c-Met.Crizotinib is a multitargeted small molecule tyrosine kinase inhibitor, which had been originally developed as an inhibitor of the mesenchymal epithelial transition growth factor (c-MET); it is also a potent inhibitor of ALK phosphorylation and signal transduction. This inhibition is associated with G1-S phase cell cycle arrest and induction of apoptosis in positive cells in vitro and in vivo. Crizotinib also inhibits the related ROS1 receptor tyrosine kinase.
References
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3876666/
side effects crizotinib (Xalkori) is an oral receptor tyrosine kinase inhibitor indicated for the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC). Common side effects with Xalkori use include upper respiratory infection, nausea, vomiting, stomach pain, decreased appetite, insomnia, dizziness, tired feeling, diarrhea, constipation, rash or itching, cold symptoms (stuffy nose, sneezing, sore throat), numbness or tingling, or swelling in your hands or feet.
http://www.rxlist.com/xalkori-side-effects-drug-center.htm
Description In August 2011, the United States FDA approved crizotinib (PF- 02341066) for the treatment of anaplastic lymphoma kinase (ALK) rearranged non-small-cell lung cancer (NSCLC). Crizotinib is a dual ATP competitive inhibitor of tyrosine kinases c-MET (Mesenchymal-Epithelial Transition Factor) kinase (cellular IC50=8 nM) and ALK (cellular IC50=20 nM), both of which are important targets for cancer chemotherapy. When crizotinib was tested for selectivity versus other kinases it was found to have enzyme IC50's within 100-fold multiples of c-MET for 13 of the 120 kinases tested. In cellular assays, crizotinib was found to inhibit RON (recepteur d’origine nantais) kinase with a 10-fold selectivity window over c-MET.
Chemical Properties White Solid
Originator Pfizer (United States)
Uses A potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). A potential antitumor agent.
Uses Crizotinib is a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). Crizotinib is a potential antitumor agent.
Uses PF-2341066 (Crizotinib) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM, respectivley
Definition ChEBI: A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients wi h locally advanced or metastatic non-small cell lung cancer (NSCLC)
Indications Crizotinib (Xalkori(R), Pfizer), approved in 2011, was the first approved inhibitor targeting anaplastic lymphoma kinase (ALK). ROS protooncogene 1-encoded kinase (ROS1) of the tyrosine kinase insulin receptor class and MET proto-oncogene-encoded kinase of the hepatocyte growth factor receptor (HGFR) class are other kinases targeted by crizotinib.When approved in 2011, crizotinib was the first drug specifically targeting NSCLC patients. However, resistance to crizotinib was usually observed in approximately 8 months after initial application and more than half of crizotinib-treated patients experienced gastrointestinal side effects. In 2016,crizotinib was additionally approved for ROS1-positive NSCLC by FDA.
Brand name Xalkori

 

Non Small Cell Lung Cancer Medications Crizotinib CAS New Medication For Lung CancerNon Small Cell Lung Cancer Medications Crizotinib CAS New Medication For Lung Cancer

Non Small Cell Lung Cancer Medications Crizotinib CAS New Medication For Lung Cancer

Non Small Cell Lung Cancer Medications Crizotinib CAS New Medication For Lung Cancer

Non Small Cell Lung Cancer Medications Crizotinib CAS New Medication For Lung CancerNon Small Cell Lung Cancer Medications Crizotinib CAS New Medication For Lung Cancer

Weifang Ruze New Material Co.,LTD supply free sample and datebase on Crizotinib (CAS No.: 877399-52-5), if you want futher information about Crizotinib (CAS No.: 877399-52-5), please feel free to contract us.

 

Contact Details
Weifang Ruze New Material Co., Ltd.

Contact Person: Ruze02

Send your inquiry directly to us (0 / 3000)